Patents by Inventor Paul A. Jaminet

Paul A. Jaminet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody-oligonucleotide conjugates
    Patent number: 12458705
    Abstract: Conjugates are provided, comprising a targeting protein, e.g., an anti-TM4SFI antibody or antigen or binding fragments thereof. Methods of manufacture and use of said conjugates are also described.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: November 4, 2025
    Assignee: ANGIEX, INC.
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Edward Ha
  • Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same
    Patent number: 12428477
    Abstract: Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Methods of use of said ADCs are also described.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: September 30, 2025
    Assignee: ANGIEX, INC.
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Edward H. Ha, Leonard G. Presta, Manish S. Hudlikar
  • ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME
    Publication number: 20250152730
    Abstract: Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, antigen-binding fragments thereof, and a linker. Methods of use of said ADCs are also described.
    Type: Application
    Filed: December 6, 2024
    Publication date: May 15, 2025
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Manish Hudlikar, Edward H. Ha
  • DEGRADER-ANTIBODY CONJUGATES AND METHODS OF USING SAME
    Publication number: 20240342302
    Abstract: Degrader-antibody conjugates (DACs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Degrader molecules as described comprise a ubiquitin E3 ligase binding group (E3LB) and a protein binding group (PB). Linkers may be utilized between the antibodies and the degrader molecules (linker L1) and between the ubiquitin E3 ligase binding group (E3LB) and the protein binding group (PB) of the degrader molecule (linker L2). Methods of use of the DACs are also described.
    Type: Application
    Filed: March 26, 2024
    Publication date: October 17, 2024
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Edward H. Ha, Manish Hudlikar, Gabriel Gonzalez, Aaron Mallek
  • COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME
    Publication number: 20240166759
    Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described and antibody drug conjugates containing the same, and combinations of such antibodies and ADCs with an immunotherapy, such as an immunomodulatory agent.
    Type: Application
    Filed: September 25, 2023
    Publication date: May 23, 2024
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Gabriel Gonzalez
  • MAYTANSINE-ANTIBODY CONJUGATES AND METHODS OF USING SAME
    Publication number: 20240156978
    Abstract: Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, antigen-binding fragments thereof, a linker and a drug. The drug is an inhibitor of tubulin polymerization. Methods of use of the ADCs are also described.
    Type: Application
    Filed: September 25, 2023
    Publication date: May 16, 2024
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Edward H. Ha, Leonard G. Presta, Manish Hudlikar, Robert Lutz
  • ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USING SAME
    Publication number: 20230372518
    Abstract: Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, antigen-binding fragments thereof, a linker and a drug. The drug is an antimitotic tetrapeptide. Methods of use of the ADCs are also described.
    Type: Application
    Filed: February 21, 2023
    Publication date: November 23, 2023
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Edward H. Ha
  • ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME
    Publication number: 20230338572
    Abstract: Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, antigen-binding fragments thereof, and a cleavable linker. Methods of use of said ADCs are also described.
    Type: Application
    Filed: January 30, 2023
    Publication date: October 26, 2023
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Edward H. Ha, L. Nathan Tumey, Aaron Mallek, Manish Hudlikar
  • ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME
    Publication number: 20230293713
    Abstract: Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, antigen-binding fragments thereof, a linker and a drug. Methods of use of said ADCs are also describe.
    Type: Application
    Filed: November 1, 2022
    Publication date: September 21, 2023
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Edward H. Ha, Manish Hudlikar
  • DEGRADER-ANTIBODY CONJUGATES AND METHODS OF USING SAME
    Publication number: 20230126271
    Abstract: Degrader-antibody conjugates (DACs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Degrader molecules as described comprise a ubiquitin E3 ligase binding group (E3LB) and a protein binding group (PB). Linkers may be utilized between the antibodies and the degrader molecules (L1) and between the ubiquitin E3 ligase binding group (E3LB) and the protein binding group (PB) of the degrader molecule (L2). Methods of use of said DACs are also described.
    Type: Application
    Filed: September 27, 2022
    Publication date: April 27, 2023
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Edward Ha, Manish S. Hudlikar, Gabriel Gonzalez
  • ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20230096824
    Abstract: Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Methods of use of said ADCs are also described.
    Type: Application
    Filed: February 27, 2020
    Publication date: March 30, 2023
    Inventors: Paul A. JAMINET, Shou-Ching S. JAMINET, Edward H. HA, Leonard G. PRESTA, Manish S. HUDLIKAR
  • ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING SAME
    Publication number: 20220267461
    Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.
    Type: Application
    Filed: November 22, 2021
    Publication date: August 25, 2022
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Harold F. Dvorak, Leonard G. Presta
  • ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING SAME
    Publication number: 20220153860
    Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.
    Type: Application
    Filed: November 22, 2021
    Publication date: May 19, 2022
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Harold F. Dvorak, Leonard G. Presta
  • Anti-TM4SF1 antibodies and methods of using same
    Patent number: 11208495
    Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: December 28, 2021
    Assignee: ANGIEX, INC.
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Harold F. Dvorak, Leonard G. Presta
  • ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
    Publication number: 20210260209
    Abstract: Conjugates are provided, comprising a targeting protein, e.g., an anti-TM4SFI antibody or antigen or binding fragments thereof. Methods of manufacture and use of said conjugates are also described.
    Type: Application
    Filed: June 12, 2019
    Publication date: August 26, 2021
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Edward Ha
  • ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING SAME
    Publication number: 20200270360
    Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.
    Type: Application
    Filed: August 28, 2018
    Publication date: August 27, 2020
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Harold F. Dvorak, Leonard G. Presta